Literature DB >> 22843767

Prostate cancer aggressiveness: in vivo assessment of MR spectroscopy and diffusion-weighted imaging at 3 T.

Thiele Kobus1, Pieter C Vos, Thomas Hambrock, Maarten De Rooij, Christina A Hulsbergen-Van de Kaa, Jelle O Barentsz, Arend Heerschap, Tom W J Scheenen.   

Abstract

PURPOSE: To determine the individual and combined performance of magnetic resonance (MR) spectroscopic imaging and diffusion-weighted (DW) imaging at 3 T in the in vivo assessment of prostate cancer aggressiveness by using histopathologically defined regions of interest on radical prostatectomy specimens to define the prostate cancer regions to be investigated.
MATERIALS AND METHODS: The local institutional ethics review board approved this retrospective study and waived the informed consent requirement. Fifty-four patients with biopsy-proved prostate cancer underwent clinical MR spectroscopic imaging followed by prostatectomy. Guided by the histopathologic map, all spectroscopy voxels that contained tumor tissue were selected, and metabolite ratios (choline [Cho] plus creatine [Cr]-to-citrate [Cit] and Cho/Cr ratios) were derived. For each spectroscopic voxel, 25th percentile apparent diffusion coefficient (ADC) of the region corresponding to that voxel was determined, representing the most aberrant tumor part on the ADC map, which was often smaller than spectroscopic imaging voxels. Maximum metabolic ratios and minimum 25th percentile ADC of each tumor were related to tumor aggressiveness and were used to differentiate aggressiveness classes. A logistic regression model (LRM) was used to combine data from both modalities.
RESULTS: Significant correlation was found between aggressiveness classes and maximum Cho+Cr/Cit ratio (ρ=0.36), maximum Cho/Cr ratio (ρ=0.35), and minimum 25th percentile ADC (ρ=-0.63) in the peripheral zone (PZ). In the transition zone (TZ), the correlation was significant for only Cho+Cr/Cit and Cho/Cr ratios (ρ=0.58 and ρ=0.60, respectively). For differentiation between aggressiveness classes, LRM use did not result in significantly improved differentiation over any individual variables.
CONCLUSION: These findings enabled confirmation that MR spectroscopic imaging and DW imaging offer potential for in vivo noninvasive assessment of prostate cancer aggressiveness, and both modalities have comparable performance. The combination did not result in better performance. Nonetheless, the better performances of metabolite ratios in the TZ and of ADCs in the PZ suggest that they have complementary value. © RSNA, 2012

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22843767     DOI: 10.1148/radiol.12111744

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  49 in total

1.  Computed diffusion-weighted imaging of the prostate at 3 T: impact on image quality and tumour detection.

Authors:  Andrew B Rosenkrantz; Hersh Chandarana; Nicole Hindman; Fang-Ming Deng; James S Babb; Samir S Taneja; Christian Geppert
Journal:  Eur Radiol       Date:  2013-06-12       Impact factor: 5.315

2.  Inter-reader agreement of the ESUR score for prostate MRI using in-bore MRI-guided biopsies as the reference standard.

Authors:  L Schimmöller; M Quentin; C Arsov; R S Lanzman; A Hiester; R Rabenalt; G Antoch; P Albers; D Blondin
Journal:  Eur Radiol       Date:  2013-06-12       Impact factor: 5.315

3.  Apparent diffusion coefficient value is a strong predictor of unsuspected aggressiveness of prostate cancer before radical prostatectomy.

Authors:  Raphaele Renard Penna; Geraldine Cancel-Tassin; Eva Comperat; Pierre Mozer; Priscilla Léon; Justine Varinot; Morgan Roupret; Marc-Olivier Bitker; Olivier Lucidarme; Olivier Cussenot
Journal:  World J Urol       Date:  2016-02-22       Impact factor: 4.226

Review 4.  Multiparametric MRI in prostate cancer management.

Authors:  Linda M Johnson; Baris Turkbey; William D Figg; Peter L Choyke
Journal:  Nat Rev Clin Oncol       Date:  2014-05-20       Impact factor: 66.675

5.  Comparison of T2(*) mapping with diffusion-weighted imaging in the characterization of low-grade vs intermediate-grade and high-grade prostate cancer.

Authors:  Lian-Ming Wu; Zi-Zhou Zhao; Xiao-Xi Chen; Qing Lu; Shi-Teng Suo; Qiang Liu; Jiani Hu; E Mark Haccke; Jian-Rong Xu
Journal:  Br J Radiol       Date:  2016-04-19       Impact factor: 3.039

6.  Utility of Restriction Spectrum Imaging Among Men Undergoing First-Time Biopsy for Suspected Prostate Cancer.

Authors:  Ely R Felker; Steven S Raman; Sepideh Shakeri; Sohrab A Mirak; Amirhossein M Bajgiran; Lorna Kwan; Pooria Khoshnoodi; Fuad F ElKhoury; Daniel J A Margolis; David Karow; David S K Lu; Nate White; Leonard S Marks
Journal:  AJR Am J Roentgenol       Date:  2019-04-30       Impact factor: 3.959

Review 7.  Functional magnetic resonance imaging and molecular pathology at the crossroad of the management of early prostate cancer.

Authors:  Raphaele Renard-Penna; Geraldine Cancel-Tassin; Eva Comperat; Morgan Roupret; Pierre Mozer; Olivier Cussenot
Journal:  World J Urol       Date:  2015-05-06       Impact factor: 4.226

8.  Improved spatial localization in magnetic resonance spectroscopic imaging with two-dimensional PSF-Choice encoding.

Authors:  Shelley HuaLei Zhang; Stephan E Maier; Lawrence P Panych
Journal:  J Magn Reson       Date:  2018-03-03       Impact factor: 2.229

9.  Multiparametric prostate MR imaging with T2-weighted, diffusion-weighted, and dynamic contrast-enhanced sequences: are all pulse sequences necessary to detect locally recurrent prostate cancer after radiation therapy?

Authors:  Olivio F Donati; Sung Il Jung; Hebert Alberto Vargas; David H Gultekin; Junting Zheng; Chaya S Moskowitz; Hedvig Hricak; Michael J Zelefsky; Oguz Akin
Journal:  Radiology       Date:  2013-03-12       Impact factor: 11.105

10.  Detection of prostate cancer with multiparametric MRI (mpMRI): effect of dedicated reader education on accuracy and confidence of index and anterior cancer diagnosis.

Authors:  Kirema Garcia-Reyes; Niccolò M Passoni; Mark L Palmeri; Christopher R Kauffman; Kingshuk Roy Choudhury; Thomas J Polascik; Rajan T Gupta
Journal:  Abdom Imaging       Date:  2015-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.